[ad_1]
© Reuters. FILE PHOTO: The phrase “COVID-19” is mirrored in a drop on a syringe needle on this illustration taken November 9, 2020. REUTERS/Dado Ruvic/Illustration/File Photograph
(Reuters) – Tonix Prescription drugs Holding Corp stated on Tuesday its experimental drug failed to satisfy the first objective in a mid-stage research for administration of widespread muscle ache and tenderness related to lengthy COVID-19.
Shares of the corporate have been down 12% in premarket buying and selling.
The 63-patient research was designed to watch the depth of ache in sufferers who had lengthy COVID and administered both the drug, TNX-102 SL, or placebo, however the trial failed to indicate enchancment at week 14 of therapy, the corporate stated.
Nonetheless, the research confirmed that the drug helped scale back fatigue and enhance sleep high quality and cognitive operate within the sufferers, the corporate stated.
Tonix intends to satisfy officers from the U.S. Meals and Drug Administration in early 2024 to hunt permission to conduct a late-stage trial that focuses on decreasing fatigue in sufferers with lengthy COVID, an sickness with no authorized medicine.
[ad_2]
Source link
